A. Collado

发表

HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study

J. Pineda, A. Rivero‐Juárez, M. Ríos, 2017, HIV clinical trials.

Paritaprevir/ritonavir/ombitasvir plus dasabuvir in HIV/HCV-coinfected patients with genotype 1 in real-life practice

J. Macías, J. Pineda, A. Rivero‐Juárez, 2018, HIV clinical trials.

Impact of interferon‐free regimens on the glomerular filtration rate during treatment of chronic hepatitis C in a real‐life cohort

J. Macías, M. Ríos, F. Téllez, 2018, Journal of viral hepatitis.

Haemophilus influenzae pneumonia in human immunodeficiency virus-infected patients. The Grupo Andaluz para el Estudio de las Enfermedades Infecciosas.

E. Cordero, J. Pachón, A. Rivero, 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain

A. Rivero‐Juárez, A. Rivero, L. López-Cortés, 2015, European Journal of Clinical Microbiology & Infectious Diseases.

Anaemia predictors in patients with chronic hepatitis C treated with ribavirin and direct-acting antiviral agents

A. Collado, E. Molina-Cuadrado, Héctor Mateo-Carrrasco, 2017, European journal of hospital pharmacy. Science and practice.

Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.

J. Macías, J. Pineda, Á. Camacho, 2011, The Journal of antimicrobial chemotherapy.

Baseline serum low-density lipoprotein cholesterol levels predict response to hepatitis C virus therapy in HIV/hepatitis C virus coinfected patients

J. Pineda, A. Rivero, L. López-Cortés, 2008, AIDS.

Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort

J. M. Rosales, J. Pascasio, J. Salmerón, 2019, PloS one.

Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy

S. Mauss, S. Scholten, J. Fehr, 2015, PloS one.

Weight changes after first-line antiretroviral initiation in a cohort of HIV-positive patients in Southern Spain (CAPOTA study)

A. Rivero, C. Hidalgo-Tenorio, Jesús Santos, 2022, International journal of STD & AIDS.

Parenteral drug use as the main barrier to hepatitis C treatment uptake in HIV‐infected patients

J. Macías, A. Rivero, F. Téllez, 2019, HIV medicine.

Usefulness of Sputum Culture for Diagnosis of Bacterial Pneumonia in HIV-Infected Patients

E. Cordero, J. Pachón, A. Rivero, 2002, European Journal of Clinical Microbiology and Infectious Diseases.

Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone.

C. Tural, V. Soriano, J. Macías, 2008, The Journal of antimicrobial chemotherapy.

Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients.

J. Pineda, A. Rivero, L. López-Cortés, 2007, The Journal of antimicrobial chemotherapy.

High efficacy of Resistance-guided retreatment of HCVpatients failing NS5A inhibitors in real world.

J. Crespo, J. Pascasio, J. Salmerón, 2019, Journal of hepatology.

Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression.

J. Macías, J. Pineda, A. Rivero, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Predictors of Severe Haematological Toxicity Secondary to Pegylated Interferon plus Ribavirin Treatment in HIV-HCV-Coinfected Patients

J. Macías, J. Pineda, A. Rivero, 2007, Antiviral therapy.

Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia

J. Macías, J. Pineda, A. Rivero, 2015, European Journal of Clinical Microbiology & Infectious Diseases.

Inﬂuence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients

J. Pineda, A. Rivero, L. López-Cortés, 2007 .

Short communication: RNASEL alleles and susceptibility to infection by human retroviruses and hepatitis viruses.

V. Soriano, P. Torres, C. de Mendoza, 2012, AIDS research and human retroviruses.

Phylodynamic and Phylogeographic Profiles of Subtype B HIV-1 Epidemics in South Spain

N. Chueca, J. Pasquau, Federico García, 2016, PloS one.

Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen.

M. Crespo, J. Esteban, J. Pineda, 2008, The Journal of antimicrobial chemotherapy.

Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy.

B. Figueruela, J. Macías, J. Pineda, 2019, Journal of hepatology.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Liver Toxicity of Current Antiretroviral Regimens in HIV-Infected Patients with Chronic Viral Hepatitis in a Real-Life Setting: The HEPAVIR SEG-HEP Cohort

J. Pineda, A. Rivero, M. Ríos, 2016, PloS one.

Hepatic Safety of Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate Fixed-Dose Single-Tablet Regimen in HIV-Infected Patients with Active Hepatitis C Virus Infection: The hEPAtic Study

J. Macías, J. Pineda, J. Hernández-Quero, 2016, PloS one.

Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals

Dao Sen Wang, M. Poljak, F. Ceccherini‐Silberstein, 2022, JHEP reports : innovation in hepatology.

High efficacy of Glecaprevir/Pibrentasvir for HCV-Infected individuals with active drug use.

L. Real, J. Macías, J. Pineda, 2022, The Journal of infection.

[Poncet's disease. Gammagraphic evidence of synovial involvement].

J. Grau, A. Collado, V. Giner, 1998, Medicina clinica.

Community-acquired bacterial pneumonia in human immunodeficiency virus-infected patients: validation of severity criteria.

E. Cordero, J. Pachón, A. Rivero, 2000 .

Prevalence of xenotropic murine leukemia virus-related virus infection in different risk populations in Spain.

V. Soriano, J. Hackett, C. de Mendoza, 2012, AIDS research and human retroviruses.

Failure to Biktarvy® and development of resistance mutations in an antiretroviral-experienced patient.

N. Chueca, Federico García, M. Álvarez, 2020, Antiviral research.

[Impact of the fibromyalgia in the chronic fatigue syndrome].

L. Aliste, J. Castro-Marrero, J. Alegre, 2014, Medicina clinica.

No evidence of firstly acquired acute hepatitis C virus infection outbreak among HIV-infected patients from Southern Spain: a multicentric retrospective study from 2000-2014

J. Macías, J. Pineda, P. Viciana, 2016, BMC Infectious Diseases.

High prevalence and diversity of HIV-1 non-B genetic forms due to immigration in southern Spain: A phylogeographic approach

N. Chueca, J. Pasquau, Federico García, 2017, PloS one.

Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain

A. Rivero, L. López-Cortés, M. Márquez, 2015, European Journal of Clinical Microbiology & Infectious Diseases.

Early emergence of opportunistic infections after starting direct‐acting antiviral drugs in HIV/HCV‐coinfected patients

J. Macías, J. Pineda, R. Palacios, 2018, Journal of viral hepatitis.

Higher relapse rate among HIV/HCV-coinfected patients receiving sofosbuvir/ledipasvir for 8 vs 12 weeks.

J. Macías, J. Pineda, R. Palacios, 2019, The Journal of infection.